卵巢癌脑转移的诊治

Diagnosis and treatment of brain metastasis from epithelial ovarian carcinoma

目的探讨卵巢癌脑转移的诊断及治疗方法。方法回顾性分析我院2008年1月-2011年8月收治的6例卵巢癌脑转移患者的临床资料,并对相关文献进行复习。结果 6例诊断时中位年龄58.5岁,均已绝经,入院时血CA125均升高,治疗后均下降;4例病情复发时伴CA125升高。依据为影像学检查发现脑转移灶。患者均接受手术及术后以铂类为基础的联合化疗,其中3例进行了放射治疗,1例行开颅手术。4例仍接受化疗,2例死亡。结论卵巢癌脑转移预后差,手术辅以铂类为基础的联合化疗及放疗是主要治疗方法 ;预后与临床期别、肿瘤分化程度及对铂类化疗药物敏感程度有关,血清CA125可用于治疗后的监测随访。

Objective To study the diagnosis and treatment of brain metastasis from epithelial ovarian carcinoma.Methods Clinical data about 6 patients with brain metastasis from ovarian cancer admitted to our hospital from January 2008 to August 2011 were retrospectively analyzed with the related literature reviewed.Results The median age of the 6 menopausal patients was 58.5 years at diagnosis.Their serum CA125 level was elevated and decreased after treatment.The CA125 level increased when the disease relapsed.CT or MRI showed intracranial metastatic lesions in the patients.Of the 6 patients who received surgery and platinum-based adjuvant chemotherapy,3 underwent radiotherapy and 1 craniotomy.Of the 4 patients who received chemotherapy,2 died.Conclusion The prognosis of patients with brain metastasis from epithelial ovarian carcinoma is poor.Surgery and platinum-based postoperative adjuvant chemotherapy and radiotherapy are the main treatment modalities for brain metastasis from epithelial ovarian carcinoma.The prognosis of brain metastasis from epithelial ovarian carcinoma is related with its clinical stage,differentiation and platinum sensitivity.Serum CA125 can be used as an indicator during follow-up.